HERON THERAPEUTICS INC

Heron Therapeutics COO buys shares amid 135% social‑media buzz, signaling bullish insider confidence and potential near‑term upside.

Insider buying by Heron Therapeutics EVP William P. Forbes signals confidence in the company’s pipeline—could be a smart entry point before next earnings.

Heron Therapeutics CFO’s latest insider buy signals confidence in its biochronomer platform, amid sharp price swings and a potential rebound.

Heron Therapeutics CEO Craig Collard’s recent RSU and share purchases signal confidence in the company’s drug‑delivery platform and upcoming milestones.

Heron Therapeutics insider buying: CFO Duarte Ira’s $0.40 purchase of 12,500 shares signals potential optimism amid an 80% plunge, but investors should weigh weak fundamentals and upcoming milestones before acting.

Heron Therapeutics insider buying sparks optimism—CEO‑level purchases signal confidence in drug‑delivery tech, potential upside, and a bullish outlook for investors.

Heron Therapeutics insider trade: CEO Collard buys 13,797 shares after selling RSUs, signalling confidence and potential upside amid upcoming governance changes.

Heron Therapeutics insiders buy shares, signaling confidence in a high‑growth biotech. See why CFO Duarte Ira’s stake boost investor optimism.

Heron Therapeutics insiders keep buying as the stock hits a 52‑week low. Forbes’ disciplined trades suggest the stock may be undervalued, hinting at a potential breakout if the biotech’s drug‑delivery platform delivers.